1. Home
  2. FLYE vs IMRN Comparison

FLYE vs IMRN Comparison

Compare FLYE & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fly-E Group Inc.

FLYE

Fly-E Group Inc.

HOLD

Current Price

$1.74

Market Cap

2.7M

Sector

Industrials

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.10

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLYE
IMRN
Founded
2018
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
9.6M
IPO Year
2024
2016

Fundamental Metrics

Financial Performance
Metric
FLYE
IMRN
Price
$1.74
$1.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.6K
25.2K
Earning Date
04-21-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
61.82
N/A
EPS
N/A
N/A
Revenue
$19,063,357.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.68
52 Week High
$21.80
$2.38

Technical Indicators

Market Signals
Indicator
FLYE
IMRN
Relative Strength Index (RSI) 43.91 47.43
Support Level $1.70 $1.07
Resistance Level $2.30 $1.24
Average True Range (ATR) 0.15 0.09
MACD -0.00 -0.01
Stochastic Oscillator 27.91 35.02

Price Performance

Historical Comparison
FLYE
IMRN

About FLYE Fly-E Group Inc.

Fly-E Group Inc is principally engaged in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the Fly E-Bike brand. The Company encourages the adoption of eco-friendly transportation for active lifestyles.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: